

March 2019

**Subject:** Health Authority Communication - Erwinase<sup>®</sup> Supply Situation

**From:** Jazz Pharmaceuticals (“Jazz”)

Dear Health Authority Representative

Further to the correspondence and updates that have been sent to the Health Authorities over the last year, Jazz would like to provide another update on the supply status for Erwinase (crisantaspase (*Erwinia* L-asparaginase)), 10,000 Units/vial.

As previously reported Erwinase is licensed from and manufactured by Porton Biopharma Limited (“PBL”), a company wholly owned by the U.K. Government’s Department of Health. In previous communications (dated November 2017, September 2018, and November 2018), Jazz has stated their intention to continue to work with PBL towards increasing and providing a stable supply of Erwinase worldwide. We continue to recognize any Erwinase supply disruption can impact patient care, and we take these supply disruptions very seriously. We are taking all possible steps to maintain distribution and ensure the seamless care of those patients who rely on Erwinase.

Unfortunately PBL has experienced and continues to experience manufacturing issues that have resulted, and continue to result, in disruptions in our ability to supply and, as such, further stock outs are anticipated through the remainder of 2019.


As previously notified, due to the ongoing supply shortages and limited product availability Jazz expects that inventory from available batches will be depleted quickly. We expect multiple batches to be released by PBL over the next 2 quarters; however due to strong demand with the introduction of a new batch, we continue to anticipate that stock outs will occur following each batch. In addition the timing of release of each batch is also subject to change.

Jazz greatly appreciates the cooperation that has been demonstrated by all of the Health Authorities in helping to support the continued supply of this medically critical drug for patients who have experienced hypersensitivity to *E. coli*-derived asparaginase treatments for Acute Lymphoblastic Leukaemia during this period of supply challenges. We continue to engage with health care providers and institutions to manage this situation as best as possible in this difficult time.


Jazz continues to work with PBL in order to manage a stable supply of Erwinase. Jazz will complete the national out of stock notifications as required for each shortage period and should there be significant changes to the supply situation, will provide a follow up communication.

Please do not hesitate to contact Julie Westaway with questions at the email or phone below.

Sincerely,



Julie Westaway  
**Associate Director, EU/RoW Strategy, Global Regulatory Affairs,**  
Jazz Pharmaceuticals UK Ltd.,  
julie.westaway@jazzpharma.com  
Office: 0044 1865 255021



Jonas Wilf  
**Director, Regulatory Strategy, Global Regulatory Affairs,**  
Jazz Pharmaceuticals Inc.,  
jonas.wilf@jazzpharma.com  
Office: 001 215 832 3762